ARDELYX, INC. Financing Cash Flow
ARDELYX, INC. (ARDX) reported Financing Cash Flow of $55.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- ARDELYX, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $49.72M, a 0.13% increase year-over-year.
- ARDELYX, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $5.44M, a 267.21% increase year-over-year.
- ARDELYX, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $557.00K, a 98.87% decline year-over-year.
- ARDELYX, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.81M, a 4.34% increase year-over-year.
- ARDELYX, INC. net cash provided by (used in) financing activities for fiscal 2025 was $54.51M, a 48.86% decline from fiscal 2024.
- ARDELYX, INC. net cash provided by (used in) financing activities for fiscal 2024 was $106.59M, a 27.14% decline from fiscal 2023.
- ARDELYX, INC. net cash provided by (used in) financing activities for fiscal 2023 was $146.29M, a 94.18% increase from fiscal 2022.
- ARDELYX, INC. net cash provided by (used in) financing activities for fiscal 2022 was $75.34M, a 9.23% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $55.16M 10-Q · filed 2026-08-06 | $55.72M derived: sum of 3 quarters · filed 2026-08-06 | $58.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.44M 10-Q · filed 2026-04-30 | $6.00M derived: sum of 2 quarters · filed 2026-04-30 | $8.81M derived: sum of 3 quarters · filed 2026-04-30 | $58.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $557.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $3.37M derived: sum of 2 quarters · filed 2026-02-19 | $53.03M derived: sum of 3 quarters · filed 2026-08-06 | $54.51M 10-K · filed 2026-02-19 |
| 2025-09-30 | $2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $52.47M derived: sum of 2 quarters · filed 2026-08-06 | $53.95M 10-Q · filed 2025-10-30 | $103.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $49.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $51.14M 10-Q · filed 2026-08-06 | $100.45M derived: sum of 3 quarters · filed 2026-08-06 | $103.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-04-30 | $50.80M derived: sum of 2 quarters · filed 2026-04-30 | $53.49M derived: sum of 3 quarters · filed 2026-04-30 | $55.10M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $49.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $52.01M derived: sum of 2 quarters · filed 2026-02-19 | $53.62M derived: sum of 3 quarters · filed 2026-02-19 | $106.59M 10-K · filed 2026-02-19 |
| 2024-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $4.30M derived: sum of 2 quarters · filed 2025-10-30 | $57.28M 10-Q · filed 2025-10-30 | $83.26M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $1.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $54.58M 10-Q · filed 2025-08-04 | $80.57M derived: sum of 3 quarters · filed 2026-02-19 | $138.44M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $52.97M 10-Q · filed 2025-05-01 | $78.96M derived: sum of 2 quarters · filed 2026-02-19 | $136.83M derived: sum of 3 quarters · filed 2026-02-19 | $148.35M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $25.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $83.86M derived: sum of 2 quarters · filed 2026-02-19 | $95.38M derived: sum of 3 quarters · filed 2026-02-19 | $146.29M 10-K · filed 2026-02-19 |
| 2023-09-30 | $57.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $69.39M derived: sum of 2 quarters · filed 2024-10-31 | $120.31M 10-Q · filed 2024-10-31 | $139.09M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $11.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $62.43M 10-Q · filed 2024-08-01 | $81.22M derived: sum of 3 quarters · filed 2025-02-20 | $115.70M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $50.92M 10-Q · filed 2024-05-02 | $69.71M derived: sum of 2 quarters · filed 2025-02-20 | $104.19M derived: sum of 3 quarters · filed 2025-02-20 | $126.32M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $18.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $53.27M derived: sum of 2 quarters · filed 2025-02-20 | $75.40M derived: sum of 3 quarters · filed 2025-02-20 | $75.34M 10-K · filed 2025-02-20 |
| 2022-09-30 | $34.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $56.62M derived: sum of 2 quarters · filed 2023-10-31 | $56.55M 10-Q · filed 2023-10-31 | $71.07M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $22.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $22.07M 10-Q · filed 2023-08-02 | $36.59M derived: sum of 3 quarters · filed 2024-02-22 | $41.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$63.00K 10-Q · filed 2023-05-03 | $14.45M derived: sum of 2 quarters · filed 2024-02-22 | $19.45M derived: sum of 3 quarters · filed 2024-02-22 | $48.17M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $14.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $19.51M derived: sum of 2 quarters · filed 2024-02-22 | $48.23M derived: sum of 3 quarters · filed 2024-02-22 | $83.00M 10-K · filed 2024-02-22 |
| 2021-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $33.72M derived: sum of 2 quarters · filed 2022-11-03 | $68.49M 10-Q · filed 2022-11-03 | $89.67M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $28.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $63.49M 10-Q · filed 2022-08-04 | $84.67M derived: sum of 3 quarters · filed 2023-03-02 | $85.47M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $34.77M 10-Q · filed 2022-05-05 | $55.95M derived: sum of 2 quarters · filed 2023-03-02 | $56.75M derived: sum of 3 quarters · filed 2023-03-02 | $56.95M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $21.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $21.98M derived: sum of 2 quarters · filed 2023-03-02 | $22.18M derived: sum of 3 quarters · filed 2023-03-02 | $22.78M 10-K · filed 2023-03-02 |
| 2020-09-30 | $798.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.00M derived: sum of 2 quarters · filed 2021-11-12 | $1.59M 10-Q · filed 2021-11-12 | $156.65M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $204.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $795.00K 10-Q · filed 2021-08-13 | $155.85M derived: sum of 3 quarters · filed 2022-02-28 | $156.07M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $591.00K 10-Q · filed 2021-05-06 | $155.65M derived: sum of 2 quarters · filed 2022-02-28 | $155.86M derived: sum of 3 quarters · filed 2022-02-28 | $155.87M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $155.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $155.27M derived: sum of 2 quarters · filed 2022-02-28 | $155.28M derived: sum of 3 quarters · filed 2022-02-28 | $155.48M 10-K · filed 2022-02-28 |
| 2019-09-30 | $213.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $218.00K derived: sum of 2 quarters · filed 2020-11-05 | $418.00K 10-Q · filed 2020-11-05 | $417.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $205.00K 10-Q · filed 2020-08-06 | $204.00K derived: sum of 3 quarters · filed 2021-03-08 | $395.00K derived: sum of 4 quarters · filed 2021-03-08 |
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-07 | $199.00K derived: sum of 2 quarters · filed 2021-03-08 | $390.00K derived: sum of 3 quarters · filed 2021-03-08 | $103.45M derived: sum of 4 quarters · filed 2021-03-08 |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $190.00K derived: sum of 2 quarters · filed 2021-03-08 | $103.25M derived: sum of 3 quarters · filed 2021-03-08 | $103.55M 10-K · filed 2021-03-08 |
| 2018-09-30 | $191.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $103.25M derived: sum of 2 quarters · filed 2019-11-06 | $103.55M 10-Q · filed 2019-11-06 | $103.56M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-06-30 | $103.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $103.36M 10-Q · filed 2019-08-09 | $103.37M derived: sum of 3 quarters · filed 2020-03-06 | $103.62M derived: sum of 4 quarters · filed 2020-03-06 |
| 2018-03-31 | $301.00K 10-Q · filed 2019-05-07 | $311.00K derived: sum of 2 quarters · filed 2020-03-06 | $562.00K derived: sum of 3 quarters · filed 2020-03-06 | $578.00K derived: sum of 4 quarters · filed 2020-03-06 |
| 2017-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-06 | $261.00K derived: sum of 2 quarters · filed 2020-03-06 | $277.00K derived: sum of 3 quarters · filed 2020-03-06 | $685.00K 10-K · filed 2020-03-06 |
| 2017-09-30 | $251.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $267.00K derived: sum of 2 quarters · filed 2018-11-07 | $675.00K 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $424.00K 10-Q · filed 2018-08-07 | ||
| 2017-03-31 | $408.00K 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | $191.20M 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $75.01M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |